Sanofi (SNYNF) News Today $94.75 0.00 (0.00%) (As of 12/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestSustainability All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Sanofi (SNYNF) Gets a Buy from JefferiesDecember 18, 2024 | markets.businessinsider.comPositive Phase 3 Trial Results for Rilzabrutinib Support Buy Rating Amidst Strong Efficacy and Safety ProfileDecember 10, 2024 | markets.businessinsider.comDZ BANK AG Sticks to Its Hold Rating for Sanofi (SNYNF)October 28, 2024 | markets.businessinsider.comSanofi (SNYNF) Receives a Sell from Deutsche BankOctober 28, 2024 | markets.businessinsider.comSanofi Q3 Profit Rises - Quick FactsOctober 25, 2024 | markets.businessinsider.comSanofi’s Strategic Moves and Financial Prospects Drive Buy RatingOctober 24, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Irhythm Technologies (IRTC)October 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Sanofi (SNY)October 21, 2024 | markets.businessinsider.comSanofi Enters Exclusive Negotiations To Sell 50% Stake In Opella To CD&ROctober 21, 2024 | markets.businessinsider.comBerenberg Bank Remains a Buy on Sanofi (SNYNF)October 18, 2024 | markets.businessinsider.comSanofi’s Strong Market Position and Growth Potential Justifies Buy RatingOctober 18, 2024 | markets.businessinsider.comDeutsche Bank Sticks to Their Sell Rating for Sanofi (SNYNF)October 16, 2024 | markets.businessinsider.comKymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech InvestorsOctober 6, 2024 | seekingalpha.comSanofi’s Market Advantage and Growth Trajectory: A Strong Buy RecommendationSeptember 26, 2024 | markets.businessinsider.comSanofi: A Strong Buy on Earnings Growth, Pipeline Progress, and Market CatalystsSeptember 20, 2024 | markets.businessinsider.comFulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses BadlySeptember 12, 2024 | seekingalpha.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN) and Sanofi (OtherSNYNF)September 12, 2024 | markets.businessinsider.comSanofi, RadioMedix, Orano Med Sign Deal For Next-Gen Radioligand Medicine For Rare CancersSeptember 12, 2024 | markets.businessinsider.comNurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated DataSeptember 4, 2024 | seekingalpha.comBuy Rating Affirmed for Sanofi Amid Promising Tolebrutinib Trials and Significant Market OpportunitySeptember 2, 2024 | markets.businessinsider.comSanofi (SNYNF) Receives a Buy from JefferiesSeptember 2, 2024 | markets.businessinsider.comSanofi: Tolebrutinib For NrSPMS Meets Primary Goal In HERCULES Trial; Fails In GEMINI Trial For RMSSeptember 2, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Gilead Sciences (GILD)July 25, 2024 | markets.businessinsider.comBuy Rating for Sanofi: Undervalued Stock with Strong Growth and Strategic InitiativesJuly 19, 2024 | markets.businessinsider.comKepler Capital Sticks to Its Hold Rating for Sanofi (SNYNF)July 19, 2024 | markets.businessinsider.comSanofi, Formation Bio, OpenAI Announce AI CollaborationMay 21, 2024 | markets.businessinsider.comBuy Rating for Sanofi: Strong Growth and Attractive Valuation Amidst Pipeline Optionality and Strategic LeadershipMay 14, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Oncolytics Biotech (ONCY), Aveanna Healthcare Holdings (AVAH) and Sanofi (OtherSNYNF)May 13, 2024 | markets.businessinsider.comSanofi Strikes COVID-19 Vaccine Agreement With Novavax; To Take Minority StakeMay 10, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Sanofi (OtherSNYNF), NewAmsterdam Pharma Company (NAMS) and Humana (HUM)April 29, 2024 | markets.businessinsider.comSanofi Q1 Profit Drops, Sales Rise; Confirms FY24 OutlookApril 25, 2024 | markets.businessinsider.comSanofi Pharma Ltd.April 23, 2024 | wsj.comSanofi succeeds in late-stage trial for blood disorder candidateApril 23, 2024 | msn.comMaintaining Buy Rating on Sanofi: A Resilient Financial Outlook Despite Currency HeadwindsApril 18, 2024 | markets.businessinsider.comNo link between weight loss drugs and suicidal thoughts, EU regulator concludesApril 12, 2024 | msn.comU.S. CDC warns bacteria causing meningitis are on the riseMarch 30, 2024 | msn.comSanofi: My Top Pick In Big PharmaMarch 25, 2024 | seekingalpha.com6 reasons to buy Teva Pharmaceuticals stock sooner than later (SNYNF)Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons whyFebruary 26, 2024 | marketbeat.comSanofi (SNYNF) Price Target Increased by 6.32% to 117.27February 24, 2024 | msn.comBuy Rating Affirmed for Sanofi on Strong Sales and Promising Financial OutlookFebruary 5, 2024 | markets.businessinsider.comPress Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology PipelineFebruary 2, 2024 | finance.yahoo.comSanofi Posts Q4 Loss, Sees Stable FY24 Business EPS; Names Nestle's Francois-Xavier Roger CFOFebruary 1, 2024 | markets.businessinsider.com20 best healthcare dividend stocks to invest in (SNYNF)Healthcare, like many other sectors, produces dividends. Learn more about how to invest in healthcare trends and earn dividends along the way with MarketBeat.January 19, 2024 | marketbeat.comSanofi: Information concerning the total number of voting rights and shares - November 2023December 18, 2023 | finance.yahoo.comTeva Pharma is the way to play the re-rise of generic drugs (SNYNF)Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growthNovember 28, 2023 | marketbeat.comInformatica soars on its AI-powered data management cloud growth (SNYNF)Enterprise cloud data management software provider Informatica Co. (NASDAQ: INFA) saw its shares surge 23% on its impressive Q3 2023 earnings report. The compaNovember 13, 2023 | marketbeat.comSanofi said to be under scrutiny over possible market manipulationNovember 7, 2023 | msn.comPfizer and Sanofi shares fall, which one to scoop up? (SNYNF)Pharmaceutical stocks aren't having a banner year; notably, two large pharmaceutical companies recently plunged to 52-week lowsNovember 7, 2023 | marketbeat.comSanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communitiesNovember 2, 2023 | finance.yahoo.comAnalyzing The Acquisition Potential Of ImmunoGenNovember 1, 2023 | msn.com Get Sanofi News Delivered to You Automatically Sign up to receive the latest news and ratings for SNYNF and its competitors with MarketBeat's FREE daily newsletter. Email Address Vladimir Lenin was right… (Ad)The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier. Including the name of the #1 company to buy. SNYNF Media Mentions By Week SNYNF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNYNF News Sentiment▼0.000.60▲Average Medical News Sentiment SNYNF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNYNF Articles This Week▼10▲SNYNF Articles Average Week Get Sanofi News Delivered to You Automatically Sign up to receive the latest news and ratings for SNYNF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies FFNTF News Today AGNPF News Today ALST News Today ALVO News Today HIPH News Today LEAS News Today ARNI News Today AZNCF News Today AVVH News Today BTMDW News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:SNYNF) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanofi Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanofi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
